Astellas Signs License For Regeneron’s VelocImmune To Bolster Antibody Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal, valued at potentially $120 million, is Regeneron’s second for the human monoclonal antibody discovery technology.
You may also be interested in...
Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.
Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.
Astellas Advances Antibody R&D Agenda With Agensys Purchase Worth Up To $537 Million
Privately held Agensys brings a proprietary portfolio of cancer targets, a preclinical pipeline of mAbs and small proteins, and antibody manufacturing capabilities.